Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients. Issue 2 (1st April 2021)

• Record Type: Journal Article
• Authors: Wei, Zhigang; Li, Qingyu; Ye, Xin; Yang, Xia; Huang, Guanghui; Li, Wenhong; Wang, Jiao; Han, Xiaoying
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 30:Issue 2(2021)
• Page Start: 106
• Page End: 114
• Publication Date: 2021-04-01
• Subjects: Non-small-cell lung cancer -- microwave ablation -- progression-free survival -- overall survival; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2019.1678173
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Objective: To evaluate the efficacy of microwave ablation (MWA) and MWA plus monochemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). Material and methods: Patients with advanced NSCLC aged ≥70 years were retrospectively enrolled. MWA was performed at the primary tumor site. The end points included progression-free survival (PFS), response to MWA and overall survival (OS). Results: Fifty-four patients were enrolled; of these, 36 received monochemotherapy. Complete ablation was achieved in 42 patients (77.8%). The median PFS and OS were 4.9 months and 21.8 months, respectively. Univariate analyses showed that female patients had superior PFS (31.9 months [95% confidence interval (CI): 0.8–63.0]) vs. 5.0 months in male patients (95% CI: 2.0–8.0), p = .002). Female sex was associated with better OS (not reached vs. 10.8 months, 95% CI: 9.3–12.3, p = .003). Moreover, patients with primary tumor size <3.5 cm had better OS than those with tumor size ≥3.5 cm (not reached vs. 10.9 months, 95% CI: 8.2–13.6, p = .006). Multivariate analyses showed that no characteristics were independent prognostic factors of PFS, but sex and primary tumor size were independent prognostic factors of OS. Conclusion: MWA was effective in the treatment of elderly patients with advanced NSCLC.